30 closest matches · ranked by relevance
Atopic Dermatitis
Primary: Comparison of Anti-YF Antibody Levels by Measurement of Log10 Neutralization Index (LNI): YFV-17D TC- (AD) Participants Compared to YFV-17D TC- (Non-AD) Participants…
Yellow Fever
Primary: The Incidence and Severity of Adverse Events in Each Treatment Group in the Double-blind Treatment Period up to 42 Days Post-vaccination. — 13; 13; 2; 22 participants
Yellow Fever
Primary: Occurrence of All Serious Adverse Events (SAEs) at Any Time During the Study — 0; 0; 0 Serious Adverse Event
Yellow Fever Vaccination Reaction
Primary: Adverse Events — 26; 27; 28 Participants
Dengue
Primary: Percentage of Participants Who Are YF and Dengue Virus (DENV)-Naive at Baseline and Are Seroprotected Against YF on Day 30 as Measured by Plaque Reduction Neutralization…
Dengue · Dengue Hemorrhagic Fever · Yellow Fever
Primary: Percentage of Flavi Virus (FV) Non-immune Participants With Seroconversion Against YF Antigen After Vaccination With Yellow Fever (YF) Vaccine (Stamaril®) Concomitantly…
Yellow Fever
Primary: Peak Neutralizing Antibody Titer — 1.37 Log YF antibody titer
Japanese Encephalitis · Yellow Fever
Primary: Number of Participants With Japanese Encephalitis Seroconversion Following ChimeriVax™-JE or STAMARIL® Alone or the Co-administration of ChimeriVax™-JE and STAMARIL®, or…
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Mean Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Following Injection (Inj.) With CYD Dengue Vaccine Dose 3: Group 1 and Group 2 — 5.38…
Dengue
Primary: Percentage of Subjects With Seropositivity Rates for Antibodies to DEN-1 - DEN-4 (ATP Cohort for Immunogenicity) — 16.7; 83.3; 16.7; 66.7 % of subjects
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Primary: Geometric Means Titers (GMTs) of Antibodies Against Each Dengue Virus Serotype Strains — NA; NA; NA; NA titers (1/dilution)
Ebolavirus Disease
Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml
Rift Valley Fever
Primary: Safety as Measured by the Number of Adverse Events — 22; 130 AEs
Influenza
Primary: HAI Antibody Immune Response to Matched Influenza Strain H1N1 A/California/04/2009 Strain — 293.4 Geometric Mean Titer
Encephalitis, Japanese B
Primary: Seroconversion Rate After Primary Vaccination — 100 percentage of seroconversion
Plasmodium Falciparum Malaria
Primary: Occurrence of Solicited Symptoms During a 8 Day Follow-up Period After Each Vaccination — 24; 11; 35; 15 events
Malaria · Malaria Vaccines
Primary: Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049 (Primary Analysis) — 452.87; 422.49 EU/mL
Zika Virus
Primary: Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reaction (ARs)-First Vaccination — 0; 0; 0; 1 Participants
Malaria · Plasmodium Falciparum Malaria
Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events
Encephalitis · Japanese Encephalitis
Primary: Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV — 2.6; 100.0; 88.2; 90.0 Percentage of participants
Japanese Encephalitis
Primary: Percentage of Participants With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 98.0; 99.3; 100.0; 100.0 percentage of participants
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions — 7 participants
Ebola Virus
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms for 7 Days After the cAd3-EBO S Vaccine Administration — 3; 3; 6; 16 Participants
Chikungunya
Primary: Number of Participants With AEs and Abnormal Lab Values, Vital Signs, and PE Findings — 11; 13; 4; 4 subjects
Monkeypox
Primary: Frequency of SAEs After First Dose of MVA-BN Vaccine — 0 Participants
Healthy Volunteers
Primary: Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30 — 97.1; 9.1; 98.7 percentage of participants
Rabies · Japanese Encephalitis
Primary: Percentages of Subjects With RVNA Concentrations ≥0.5 IU/mL At 7 Days After Last Active Vaccination — 100; 100 Percentages of subjects
Japanese Encephalitis
Primary: SCR (Seroconversion Rate) at Day 56 — 41.2; 97.3; 25.6 percentage of participants — p=>0.99
Japanese Encephalitis
Primary: Percentage of Subjects With Seroconversion Rate (SCR) ≥ 1:10 Anti-JEV Neutralizing Antibody Titer (PRNT) — 81.8 percentage of subjects
Influenza
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H10ssF-6473 Product Administration — 3; 9; 5; 17 Participants